What is the current valuation of Relmada Therapeutics’s Esmethadone Hydrochloride

Esmethadone Hydrochloride is a small molecule commercialized by Relmada Therapeutics, with a leading Phase II program in Treatment Resistant Depression. According to Globaldata, it is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Esmethadone Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Esmethadone Hydrochloride is expected to reach an annual total of $223 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Esmethadone Hydrochloride Overview

REL-1017 (D-methadone) is under development for the treatment of major depressive disorder, treatment resistant depression. The drug candidate is administered through oral route as a solution and tablet. The drug candidate is a nonopioid analgesic which acts by targeting N-methyl-D-aspartate (NMDA) receptor. It is a d optical isomer of racemic methadone. It is a new chemical entity.

It was also under development for the treatment of post herpetic neuralgia, Rett syndrome, ophthalmology, mitochondrial diseases, amyotrophic lateral sclerosis, substance (drug) abuse and neuropathic pain and restless leg syndrome.

Relmada Therapeutics Overview

Relmada Therapeutics, formerly Camp Nine, is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product esmethadone is used for the treatment of central nervous system (CNS) diseases and other disorders. It conducts various phases of clinical trials like Phase I and II. The company also carries out research and development. Relmada Therapeutics is headquartered in Coral Gables, Florida, the US.

The operating loss of the company was US$125.7 million in FY2021, compared to an operating loss of US$60.8 million in FY2020. The net loss of the company was US$125.8 million in FY2021, compared to a net loss of US$59.5 million in FY2020.

For a complete picture of Esmethadone Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.